Northern Trust’s Monopar Therapeutics MNPR Stock Holding History

Northern Trust’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Buy	31,862 +1,374	+5%	+$83K	﹤0.01%	3045
2025 Q4	$1.99M	Buy	30,488 +3,633	+14%	+$297K	﹤0.01%	3005
2025 Q3	$2.19M	Sell	26,855 -4,958	-16%	-$222K	﹤0.01%	2989
2025 Q2	$1.14M	Buy	31,813 +22,652	+247%	+$823K	﹤0.01%	3312
2025 Q1	$334K	Buy	+9,161	New	+$330K	﹤0.01%	3747
2023 Q2	–	Sell	-7,410	Closed	-$51.5K	–	4574
2023 Q1	$51.5K	Buy	7,410 +194	+3%	+$2.87K	﹤0.01%	4261
2022 Q4	$85.5K	Sell	7,216 -59	-0.8%	-$720	﹤0.01%	4144
2022 Q3	$55K	Buy	7,275 +234	+3%	+$2.22K	﹤0.01%	4298
2022 Q2	$81K	Hold	7,041	–	–	﹤0.01%	4251
2022 Q1	$90K	Sell	7,041 -143	-2%	-$2.11K	﹤0.01%	4383
2021 Q4	$115K	Sell	7,184 -84	-1%	-$1.86K	﹤0.01%	4379
2021 Q3	$177K	Buy	7,268 +47	+0.7%	+$1.22K	﹤0.01%	4228
2021 Q2	$213K	Buy	7,221 +21	+0.3%	+$601	﹤0.01%	4142
2021 Q1	$223K	Sell	7,200 -4,559	-39%	-$166K	﹤0.01%	4077
2020 Q4	$360K	Sell	11,759 -1,191	-9%	-$30.7K	﹤0.01%	3809
2020 Q3	$347K	Buy	12,950 +2,999	+30%	+$96.9K	﹤0.01%	3680
2020 Q2	$372K	Buy	+9,951	New	+$382K	﹤0.01%	3618

Other funds holding MNPR

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Northern Trust's MNPR Position: Q1 2026 in Review

Northern Trust increased its Monopar Therapeutics (MNPR) stake by 4.5% in Q1 2026, buying an estimated $83K and bringing the position to 31,862 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3045.

Northern Trust first reported a position in MNPR in Q2 2020 and has held it in 17 quarters since. The position peaked at $2.19M in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

Northern Trust held 31,862 shares of Monopar Therapeutics worth $1.75M as of Q1 2026.
Northern Trust bought 1,374 Monopar Therapeutics shares in Q1 2026, an estimated $83K.
Monopar Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3045 holding.
Northern Trust first reported a position in Monopar Therapeutics in Q2 2020 and has held it in 17 quarters since.
Northern Trust's Monopar Therapeutics position peaked at $2.19M in Q3 2025.
82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.